A New Rnase Sheds Light on the Rnase/Angiogenin Subfamily from Zebrafish
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Genetic Studies of Bipolar Disorder in Patients Selectedby Their Treatment
medigraphic Artemisaen línea Salud Mental 2008;31:431-440 Genetic studies of bipolar disorder Genetic studies of bipolar disorder in patients selected by their treatment response* Abigail Ortiz-Domínguez,1 Martin Alda1 Conferencia magistral SUMMARY rapid cycling and non-episodic course in the lamotrigine group) and co-morbidity, with the lamotrigine-responder group showing a higher Bipolar disorder (BD) is a major mood disorder with several genes frequency of panic attacks and substance abuse. of moderate or small effect contributing to the genetic susceptibility. In conclusion, pharmacogenetic studies may provide important It is also likely heterogeneous, which stimulated efforts to refine its clues to the nature of bipolar disorder and the response to long term clinical phenotype, studies investigating the link between BD treatment. susceptibility and response to a specific mood stabilizer appear to be one of the promising directions. Key words: Lithium response, pharmacogenetic, probands. In particular, excellent response to lithium prophylaxis has been described as a clinical marker of a more homogeneous subgroup of BD, characterized by an episodic course, low rates of co-morbid RESUMEN conditions, absence of rapid cycling, and a strong genetic loading. These results also suggest that lithium response clusters in families El trastorno bipolar (TB) es un trastorno afectivo con varios genes, de (independent of the increased familial loading for affective disorders), efecto leve o moderado, que contribuyen a su susceptibilidad. Es likely on a genetic basis. asimismo un trastorno heterogéneo, lo que ha estimulado diversas For almost 40 years, clinical studies have pointed to differences iniciativas para refinar el fenotipo de los pacientes con este trastor- between lithium responders (LR) and non-responders (LNR). -
The Role and Mechanisms of Action of Micrornas in Cancer Drug Resistance Wengong Si1,2,3, Jiaying Shen4, Huilin Zheng1,5 and Weimin Fan1,6*
Si et al. Clinical Epigenetics (2019) 11:25 https://doi.org/10.1186/s13148-018-0587-8 REVIEW Open Access The role and mechanisms of action of microRNAs in cancer drug resistance Wengong Si1,2,3, Jiaying Shen4, Huilin Zheng1,5 and Weimin Fan1,6* Abstract MicroRNAs (miRNAs) are small non-coding RNAs with a length of about 19–25 nt, which can regulate various target genes and are thus involved in the regulation of a variety of biological and pathological processes, including the formation and development of cancer. Drug resistance in cancer chemotherapy is one of the main obstacles to curing this malignant disease. Statistical data indicate that over 90% of the mortality of patients with cancer is related to drug resistance. Drug resistance of cancer chemotherapy can be caused by many mechanisms, such as decreased antitumor drug uptake, modified drug targets, altered cell cycle checkpoints, or increased DNA damage repair, among others. In recent years, many studies have shown that miRNAs are involved in the drug resistance of tumor cells by targeting drug-resistance-related genes or influencing genes related to cell proliferation, cell cycle, and apoptosis. A single miRNA often targets a number of genes, and its regulatory effect is tissue-specific. In this review, we emphasize the miRNAs that are involved in the regulation of drug resistance among different cancers and probe the mechanisms of the deregulated expression of miRNAs. The molecular targets of miRNAs and their underlying signaling pathways are also explored comprehensively. A holistic understanding of the functions of miRNAs in drug resistance will help us develop better strategies to regulate them efficiently and will finally pave the way toward better translation of miRNAs into clinics, developing them into a promising approach in cancer therapy. -
140503 IPF Signatures Supplement Withfigs Thorax
Supplementary material for Heterogeneous gene expression signatures correspond to distinct lung pathologies and biomarkers of disease severity in idiopathic pulmonary fibrosis Daryle J. DePianto1*, Sanjay Chandriani1⌘*, Alexander R. Abbas1, Guiquan Jia1, Elsa N. N’Diaye1, Patrick Caplazi1, Steven E. Kauder1, Sabyasachi Biswas1, Satyajit K. Karnik1#, Connie Ha1, Zora Modrusan1, Michael A. Matthay2, Jasleen Kukreja3, Harold R. Collard2, Jackson G. Egen1, Paul J. Wolters2§, and Joseph R. Arron1§ 1Genentech Research and Early Development, South San Francisco, CA 2Department of Medicine, University of California, San Francisco, CA 3Department of Surgery, University of California, San Francisco, CA ⌘Current address: Novartis Institutes for Biomedical Research, Emeryville, CA. #Current address: Gilead Sciences, Foster City, CA. *DJD and SC contributed equally to this manuscript §PJW and JRA co-directed this project Address correspondence to Paul J. Wolters, MD University of California, San Francisco Department of Medicine Box 0111 San Francisco, CA 94143-0111 [email protected] or Joseph R. Arron, MD, PhD Genentech, Inc. MS 231C 1 DNA Way South San Francisco, CA 94080 [email protected] 1 METHODS Human lung tissue samples Tissues were obtained at UCSF from clinical samples from IPF patients at the time of biopsy or lung transplantation. All patients were seen at UCSF and the diagnosis of IPF was established through multidisciplinary review of clinical, radiological, and pathological data according to criteria established by the consensus classification of the American Thoracic Society (ATS) and European Respiratory Society (ERS), Japanese Respiratory Society (JRS), and the Latin American Thoracic Association (ALAT) (ref. 5 in main text). Non-diseased normal lung tissues were procured from lungs not used by the Northern California Transplant Donor Network. -
Supplemental Information For
Supplemental Information for: Gene Expression Profiling of Pediatric Acute Myelogenous Leukemia Mary E. Ross, Rami Mahfouz, Mihaela Onciu, Hsi-Che Liu, Xiaodong Zhou, Guangchun Song, Sheila A. Shurtleff, Stanley Pounds, Cheng Cheng, Jing Ma, Raul C. Ribeiro, Jeffrey E. Rubnitz, Kevin Girtman, W. Kent Williams, Susana C. Raimondi, Der-Cherng Liang, Lee-Yung Shih, Ching-Hon Pui & James R. Downing Table of Contents Section I. Patient Datasets Table S1. Diagnostic AML characteristics Table S2. Cytogenetics Summary Table S3. Adult diagnostic AML characteristics Table S4. Additional T-ALL characteristics Section II. Methods Table S5. Summary of filtered probe sets Table S6. MLL-PTD primers Additional Statistical Methods Section III. Genetic Subtype Discriminating Genes Figure S1. Unsupervised Heirarchical clustering Figure S2. Heirarchical clustering with class discriminating genes Table S7. Top 100 probe sets selected by SAM for t(8;21)[AML1-ETO] Table S8. Top 100 probe sets selected by SAM for t(15;17) [PML-RARα] Table S9. Top 63 probe sets selected by SAM for inv(16) [CBFβ-MYH11] Table S10. Top 100 probe sets selected by SAM for MLL chimeric fusion genes Table S11. Top 100 probe sets selected by SAM for FAB-M7 Table S12. Top 100 probe sets selected by SAM for CBF leukemias (whole dataset) Section IV. MLL in combined ALL and AML dataset Table S13. Top 100 probe sets selected by SAM for MLL chimeric fusions irrespective of blast lineage (whole dataset) Table S14. Class discriminating genes for cases with an MLL chimeric fusion gene that show uniform high expression, irrespective of blast lineage Section V. -
Essential Role of the Tyrosine Kinase Substrate Phospholipase C-␥1 in Mammalian Growth and Development
Proc. Natl. Acad. Sci. USA Vol. 94, pp. 2999–3003, April 1997 Cell Biology Essential role of the tyrosine kinase substrate phospholipase C-g1 in mammalian growth and development QUN-SHENG JI*, GLENN E. WINNIER†,KEVIN D. NISWENDER‡,DEBRA HORSTMAN*, RON WISDOM*§, MARK A. MAGNUSON‡, AND GRAHAM CARPENTER*§¶ Departments of *Biochemistry, †Cell Biology, ‡Molecular Physiology and Biophysics, and §Medicine, Vanderbilt University School of Medicine, Nashville, TN 37232 Communicated by Stanley Cohen, Vanderbilt University School of Medicine, Nashville, TN, January 6, 1997 (received for review November 14, 1996) ABSTRACT The activation of many tyrosine kinases METHODS AND MATERIALS leads to the phosphorylation and activation of phospholipase C-g1 (PLC-g1). To examine the biological function of this PLC-g1 Genomic DNA and Construction of Targeting protein, homologous recombination has been used to selec- Vectors. A 129ySvJ mouse genomic DNA library (Stratagene) tively disrupt the Plcg1 gene in mice. Homozygous disruption was screened using a l-kb mouse cDNA fragment that encodes both SH2 domains of PLC-g1 (11) as a probe (a gift from B. of Plcg1 results in embryonic lethality at approximately 6 embryonic day (E) 9.0. Histological analysis indicates that Margolis, University of Michigan). Of '1 3 10 phage plaques screened, two overlapping clones encompassing 26.6 kb of Plcg1 (2y2) embryos appear normal at E 8.5 but fail to continue normal development and growth beyond E 8.5–E9.0. Plcg1 genomic DNA were obtained. Sequencing of BamHI– These results clearly demonstrate that PLC-g1 with, by in- BamHI subclones identified a 2.9-kb fragment containing ference, its capacity to mobilize second messenger molecules exons corresponding to the X domain and both SH2 domains is an essential signal transducing molecule whose absence is of rat PLC-g1. -
Author's Personal Copy
Author's personal copy Provided for non-commercial research and educational use only. Not for reproduction, distribution or commercial use. This article was originally published in the book Encyclopedia of Immunobiology, published by Elsevier, and the attached copy is provided by Elsevier for the author's benefit and for the benefit of the author's institution, for non-commercial research and educational use including without limitation use in instruction at your institution, sending it to specific colleagues who you know, and providing a copy to your institution's administrator. All other uses, reproduction and distribution, including without limitation commercial reprints, selling or licensing copies or access, or posting on open internet sites, your personal or institution’s website or repository, are prohibited. For exceptions, permission may be sought for such use through Elsevier’s permissions site at: http://www.elsevier.com/locate/permissionusematerial From Myers, D.R., Roose, J.P., 2016. Kinase and Phosphatase Effector Pathways in T Cells. In: Ratcliffe, M.J.H. (Editor in Chief), Encyclopedia of Immunobiology, Vol. 3, pp. 25–37. Oxford: Academic Press. Copyright © 2016 Elsevier Ltd. unless otherwise stated. All rights reserved. Academic Press Author's personal copy Kinase and Phosphatase Effector Pathways in T Cells Darienne R Myers and Jeroen P Roose, University of California, San Francisco (UCSF), San Francisco, CA, USA Ó 2016 Elsevier Ltd. All rights reserved. Abstract Multiple interconnected effector pathways mediate the activation of T cells following recognition of cognate antigen. These kinase and phosphatase pathways link proximal T cell receptor (TCR) signaling to changes in gene expression and cell physiology. -
1H HR-MAS and Genomic Analysis of Human Tumor Biopsies Discriminate Between High and Low Grade Astrocytomas Valeria Righi A,B,C, Jose M
Research Article Received: 16 April 2008, Revised: 22 January 2009, Accepted: 22 January 2009, Published online in Wiley InterScience: 2009 (www.interscience.wiley.com) DOI:10.1002/nbm.1377 1H HR-MAS and genomic analysis of human tumor biopsies discriminate between high and low grade astrocytomas Valeria Righi a,b,c, Jose M. Rodad, Jose´ Pazd, Adele Muccib, Vitaliano Tugnolic, Gemma Rodriguez-Tarduchya, Laura Barriose, Luisa Schenettib, Sebastia´n Cerda´na* and Marı´a L. Garcı´a-Martı´na,y We investigate the profile of choline metabolites and the expression of the genes of the Kennedy pathway in biopsies of human gliomas (n ¼ 23) using 1H High Resolution Magic Angle Spinning (HR-MAS, 11.7 Tesla, 277 K, 4000 Hz) and individual genetic assays. 1H HR-MAS spectra allowed the resolution and relative quantification by the LCModel of the resonances from choline (Cho), phosphocholine (PC) and glycerophosphorylcholine (GPC), the three main components of the combined tCho peak observed in gliomas by in vivo 1H NMR spectroscopy. All glioma biopsies depicted a prominent tCho peak. However, the relative contributions of Cho, PC, and GPC to tCho were different for low and high grade gliomas. Whereas GPC is the main component in low grade gliomas, the high grade gliomas show a dominant contribution of PC. This circumstance allowed the discrimination of high and low grade gliomas by 1H HR-MAS, a result that could not be obtained using the tCho/Cr ratio commonly used by in vivo 1H NMR spectroscopy. The expression of the genes involved in choline metabolism has been investigated in the same biopsies. -
Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients with Stable Coronary Heart Disease
Supplementary Online Content Ganz P, Heidecker B, Hveem K, et al. Development and validation of a protein-based risk score for cardiovascular outcomes among patients with stable coronary heart disease. JAMA. doi: 10.1001/jama.2016.5951 eTable 1. List of 1130 Proteins Measured by Somalogic’s Modified Aptamer-Based Proteomic Assay eTable 2. Coefficients for Weibull Recalibration Model Applied to 9-Protein Model eFigure 1. Median Protein Levels in Derivation and Validation Cohort eTable 3. Coefficients for the Recalibration Model Applied to Refit Framingham eFigure 2. Calibration Plots for the Refit Framingham Model eTable 4. List of 200 Proteins Associated With the Risk of MI, Stroke, Heart Failure, and Death eFigure 3. Hazard Ratios of Lasso Selected Proteins for Primary End Point of MI, Stroke, Heart Failure, and Death eFigure 4. 9-Protein Prognostic Model Hazard Ratios Adjusted for Framingham Variables eFigure 5. 9-Protein Risk Scores by Event Type This supplementary material has been provided by the authors to give readers additional information about their work. Downloaded From: https://jamanetwork.com/ on 10/02/2021 Supplemental Material Table of Contents 1 Study Design and Data Processing ......................................................................................................... 3 2 Table of 1130 Proteins Measured .......................................................................................................... 4 3 Variable Selection and Statistical Modeling ........................................................................................ -
S41598-021-81940-Y.Pdf
www.nature.com/scientificreports OPEN Understanding the genetic architecture of the metabolically unhealthy normal weight and metabolically healthy obese phenotypes in a Korean population Jae‑Min Park1,2,5, Da‑Hyun Park3,5, Youhyun Song1, Jung Oh Kim3, Ja‑Eun Choi3, Yu‑Jin Kwon4, Seong‑Jin Kim3, Ji‑Won Lee1* & Kyung‑Won Hong3* Understanding the mechanisms underlying the metabolically unhealthy normal weight (MUHNW) and metabolically healthy obese (MHO) phenotypes is important for developing strategies to prevent cardiometabolic diseases. Here, we conducted genome‑wide association studies (GWASs) to identify the MUHNW and MHO genetic indices. The study dataset comprised genome‑wide single‑nucleotide polymorphism genotypes and epidemiological data from 49,915 subjects categorised into four phenotypes—metabolically healthy normal weight (MHNW), MUHNW, MHO, and metabolically unhealthy obese (MUHO). We conducted two GWASs using logistic regression analyses and adjustments for confounding variables (model 1: MHNW versus MUHNW and model 2: MHO versus MUHO). GCKR, ABCB11, CDKAL1, LPL, CDKN2B, NT5C2, APOA5, CETP, and APOC1 were associated with metabolically unhealthy phenotypes among normal weight individuals (model 1). LPL, APOA5, and CETP were associated with metabolically unhealthy phenotypes among obese individuals (model 2). The genes common to both models are related to lipid metabolism (LPL, APOA5, and CETP), and those associated with model 1 are related to insulin or glucose metabolism (GCKR, CDKAL1, and CDKN2B). This study reveals the genetic architecture of the MUHNW and MHO phenotypes in a Korean population‑based cohort. These fndings could help identify individuals at a high metabolic risk in normal weight and obese populations and provide potential novel targets for the management of metabolically unhealthy phenotypes. -
Advances in Applying Computer-Aided Drug Design for Neurodegenerative Diseases
International Journal of Molecular Sciences Review Advances in Applying Computer-Aided Drug Design for Neurodegenerative Diseases Mootaz M. Salman 1,2,*,† , Zaid Al-Obaidi 3,4,†, Philip Kitchen 5 , Andrea Loreto 1,6, Roslyn M. Bill 5 and Richard Wade-Martins 1,2,* 1 Department of Physiology, Anatomy and Genetics, University of Oxford, Parks Road, Oxford OX1 3QX, UK; [email protected] 2 Oxford Parkinson’s Disease Centre, University of Oxford, South Parks Road, Oxford OX1 3QX, UK 3 Department of Pharmaceutical Chemistry, College of Pharmacy, University of Alkafeel, Najaf 54001, Iraq; [email protected] 4 Department of Chemistry and Biochemistry, College of Medicine, University of Kerbala, Karbala 56001, Iraq 5 School of Biosciences, College of Health and Life Sciences, Aston University, Aston Triangle, Birmingham B4 7ET, UK; [email protected] (P.K.); [email protected] (R.M.B.) 6 John Van Geest Centre for Brain Repair, University of Cambridge, Cambridge CB2 0PY, UK * Correspondence: [email protected] (M.M.S.); [email protected] (R.W.-M.) † Equal contribution. Abstract: Neurodegenerative diseases (NDs) including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and Huntington’s disease are incurable and affect millions of people worldwide. The development of treatments for this unmet clinical need is a major global research challenge. Computer-aided drug design (CADD) methods minimize the huge number of ligands that could be screened in biological assays, reducing the cost, time, and effort required to develop Citation: Salman, M.M.; Al-Obaidi, new drugs. -
Potent Lipolytic Activity of Lactoferrin in Mature Adipocytes
Biosci. Biotechnol. Biochem., 77 (3), 566–571, 2013 Potent Lipolytic Activity of Lactoferrin in Mature Adipocytes y Tomoji ONO,1;2; Chikako FUJISAKI,1 Yasuharu ISHIHARA,1 Keiko IKOMA,1;2 Satoru MORISHITA,1;3 Michiaki MURAKOSHI,1;4 Keikichi SUGIYAMA,1;5 Hisanori KATO,3 Kazuo MIYASHITA,6 Toshihide YOSHIDA,4;7 and Hoyoku NISHINO4;5 1Research and Development Headquarters, Lion Corporation, 100 Tajima, Odawara, Kanagawa 256-0811, Japan 2Department of Supramolecular Biology, Graduate School of Nanobioscience, Yokohama City University, 3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa 236-0004, Japan 3Food for Life, Organization for Interdisciplinary Research Projects, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113-8657, Japan 4Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamigyou-ku, Kyoto 602-8566, Japan 5Research Organization of Science and Engineering, Ritsumeikan University, 1-1-1 Nojihigashi, Kusatsu, Shiga 525-8577, Japan 6Department of Marine Bioresources Chemistry, Faculty of Fisheries Sciences, Hokkaido University, 3-1-1 Minatocho, Hakodate, Hokkaido 041-8611, Japan 7Kyoto City Hospital, 1-2 Higashi-takada-cho, Mibu, Nakagyou-ku, Kyoto 604-8845, Japan Received October 22, 2012; Accepted November 26, 2012; Online Publication, March 7, 2013 [doi:10.1271/bbb.120817] Lactoferrin (LF) is a multifunctional glycoprotein resistance, high blood pressure, and dyslipidemia. To found in mammalian milk. We have shown in a previous prevent progression of metabolic syndrome, lifestyle clinical study that enteric-coated bovine LF tablets habits must be improved to achieve a balance between decreased visceral fat accumulation. To address the energy intake and consumption. In addition, the use of underlying mechanism, we conducted in vitro studies specific food factors as helpful supplements is attracting and revealed the anti-adipogenic action of LF in pre- increasing attention. -
Antitumor Effect of TAT-Oxygen-Dependent Degradation-Caspase-3 Fusion Protein Specifically Stabilized and Activated in Hypoxic Tumor Cells
[CANCER RESEARCH 62, 2013–2018, April 1, 2002] Antitumor Effect of TAT-Oxygen-dependent Degradation-Caspase-3 Fusion Protein Specifically Stabilized and Activated in Hypoxic Tumor Cells Hiroshi Harada, Masahiro Hiraoka, and Shinae Kizaka-Kondoh1 Pharmaceuticals Division, Pharmaceutical R&D Department, POLA Chemical Industries, Inc., Totsuka-ku, Yokohama 244-0812 [H. H.]; Department of Therapeutic Radiology and Oncology, Kyoto University Graduate School of Medicine, Shogoin, Sakyo-ku, Kyoto 606-8507 [M. H.]; and Department of Molecular Oncology, Kyoto University Graduate School of Medicine, Sakyo-ku, Kyoto 606-8501 [S. K-K.], Japan ABSTRACT The ODD domain of HIF-1␣ is located in its central region and consists of ϳ200 amino acid residues. The ODD domain controls the Human solid tumors contain hypoxic regions that have considerably degradation of HIF-1␣ by the ubiquitin-proteasome pathway, and the lower oxygen tension than normal tissues. These impart resistance to deletion of this entire region is required for DNA binding and trans- radiotherapy and anticancer chemotherapy, as well as predisposing to increased tumor metastases. To develop a potentially therapeutic protein activation in the absence of hypoxic signaling (15). Recently, the drug highly specific for solid tumors, we constructed fusion proteins product of von Hippel-Lindau tumor suppressor gene was reported to selectively stabilized in hypoxic tumor cells. A model fusion protein, mediate ubiquitination and proteasomal degradation of HIF-1␣ under oxygen-dependent degradation (ODD)--galactosidase (-Gal), composed normoxic conditions by interaction with the core of the ODD domain of a part of the ODD domain of hypoxia-inducible factor-1␣ fused to of HIF-1␣ (16–18).